retatrutide type 2 diabetes phase 2 trial 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending A New Obesity Drug Delivered

Rare but serious effectssuch as pancreatitis or thyroid-related issuesshould be discussed with your provider

Inflammatory markers improved

Learn about Retatrutide (GGG tri-agonist) medication Retatrutide is an up and coming medication, still in clinical trials and does not yet have a known time when it will be approved for use or available to the general public

To date, liraglutide, and the more effective once-weekly semaglutide, have been approved in the US and Europe for the treatment of obesity, with unprecedented weight loss of up to 1520%

Mochi leans on one-on-one video visits with providers and dietitians

Week 3-4 and beyond: When things get more sensitive: Once you hit around week 3-4 (thats when youd miss your period and take a test), things change